Myasthenia gravis treatment has seen remarkable progress, with FDA approval of a first-in-class drug targeting autoimmunity. Additionally, more than 20 therapies are currently in development, ranging from pre-clinical stages to Phase 3 trials.This new and expanded edition explores these new therapies and other new developments in MG. The book retains its comprehensive review of MG, covering clinical presentation, laboratory and electrophysiological diagnosis, and treatment. These chapters offer neurologists and neuromuscular experts the latest insights into state-of-the-art patient care. The text then delves into focused chapters on epidemiology, genetics, and cancer-associated MG, broadening the appeal to scientists exploring the autoimmune drivers linked to tumors and the genetic underpinnings of MG pathophysiology.Chapters on related disorders are included due to their clinical and pathological similarities to MG. These sections provide valuable insights into antibody-mediated diseases that mirror MG in their clinical manifestations. Finally, the book concludes with chapters on clinical trial design, biomarker development, and the psychological impact of MG on patients. These chapters are essential not only for academic clinical investigators but also for professionals in the pharmaceutical industry, from research scientists to clinical trial developers.Myasthenia Gravis and Related Disorders, 4th Edition is the definitive resource for researchers and clinicians in this rapidly evolving field.
